HIV Infections Clinical Trial
The IMAGE Study is a cluster randomised trial of a structural intervention for the prevention of HIV and gender based violence being conducted in South Africa.
Background : While there is a high level of knowledge on HIV/AIDS in rural South Africa,
structural factors, including poverty and gender inequalities, have critically impeded
prevention efforts based on modifying individual risk. Attempts to rigorously evaluate
structural interventions for the prevention of HIV infection in sub-Saharan Africa remain
under-developed.
Microfinance is a well-established development tool with nearly 100 million clients world
wide. Loans to poor households, particularly to women, facilitate business development
opportunities. Prior research has demonstrated significant economic and social benefits.
Health benefits have also been documented and include improvements in immunization coverage,
better nutrition, and contraceptive use. While poverty and HIV/AIDS frequently co-exist, the
impact of microfinance on vulnerability to HIV has not previously been explored.
Intervention Design : The IMAGE intervention combines two components:
1. Microfinance: Implementation of a community-level, poverty-focused microfinance
programme exclusively targeting women
2. Gender and HIV training: A two phase participatory learning and action curriculum, has
been integrated into bi-weekly microfinance meetings. The first phase consists of 10
structured sessions facilitated by trainers, while the second phase facilitates
community mobilsation activities from within the microfinance centre.
Study Design
The IMAGE Study randomised four pairs of communities that were matched on size and
accessibility. The intervention communities received the IMAGE intervention from late 2001.
Comparison communities will receive the intervention strategy approximately three years
later.
The study enrols individuals into three pairs of cohorts (intervention and comparison). Data
is collected on the major health-related endpoints as detailed below. Qualitative and
quantitative data are also collected to document processes of change and potential pathways
of impact. Data analysis will be appropriate to the cluster-randomised study design.
Cohort I : Women recruited to IMAGE intervention and Randomly selected women eligible to
join IMAGE from control villages. Sample size per arm - 450. Length of follow up - 2 years.
Primary outcomes: 12 month experience of intimate partner violence
Cohort II : Young people aged 14-35 living in the households of women in cohort I
(Intervention and Comparison). Project sample size per arm - 750. Duration of follow up - 2
years. Primary outcomes - Condom use with last non-spousal partner
Cohort III : Randomly selected young people aged 14-35 living in Intervention communities
and Comparison communities. Project sample size per arm - 1500. Duration of follow up - 3
years. Primary outcomes - Condom use with last non-spousal partner, HIV incidence
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |